Omega-3-acid ethyl esters therapeutics - Trygg Pharma

Drug Profile

Omega-3-acid ethyl esters therapeutics - Trygg Pharma

Alternative Names: AKR-963; AKR-996; Omtryg

Latest Information Update: 28 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trygg Pharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Lipid modulators; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertriglyceridaemia
  • Research Myocardial infarction

Most Recent Events

  • 27 Mar 2015 Early research in Myocardial infarction (Prevention, Adjunctive treatment) in Norway (PO) (Trygg Pharma, pipeline, March 2015)
  • 24 Jun 2014 Launched for Hypertriglyceridaemia (Adjunctive treatment) in USA (PO)
  • 23 Apr 2014 Registered for Hypertriglyceridaemia (Adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top